High-Dose Acetylcysteine in Idiopathic Pulmonary Fibrosis
- 24 November 2005
- journal article
- research article
- Published by Massachusetts Medical Society in The New England Journal of Medicine
- Vol. 353 (21), 2229-2242
- https://doi.org/10.1056/nejmoa042976
Abstract
Idiopathic pulmonary fibrosis is a chronic progressive disorder with a poor prognosis. We conducted a double-blind, randomized, placebo-controlled multicenter study that assessed the effectiveness over one year of a high oral dose of acetylcysteine (600 mg three times daily) added to standard therapy with prednisone plus azathioprine. The primary end points were changes between baseline and month 12 in vital capacity and in single-breath carbon monoxide diffusing capacity (DLCO). A total of 182 patients were randomly assigned to treatment (92 to acetylcysteine and 90 to placebo). Of these patients, 155 (80 assigned to acetylcysteine and 75 to placebo) had usual interstitial pneumonia, as confirmed by high-resolution computed tomography and histologic findings reviewed by expert committees, and did not withdraw consent before the start of treatment. Fifty-seven of the 80 patients taking acetylcysteine (71 percent) and 51 of the 75 patients taking placebo (68 percent) completed one year of treatment. Acetylcysteine slowed the deterioration of vital capacity and DLCO: at 12 months, the absolute differences in the change from baseline between patients taking acetylcysteine and those taking placebo were 0.18 liter (95 percent confidence interval, 0.03 to 0.32), or a relative difference of 9 percent, for vital capacity (P=0.02), and 0.75 mmol per minute per kilopascal (95 percent confidence interval, 0.27 to 1.23), or 24 percent, for DLCO (P=0.003). Mortality during the study was 9 percent among patients taking acetylcysteine and 11 percent among those taking placebo (P=0.69). There were no significant differences in the type or severity of adverse events between patients taking acetylcysteine and those taking placebo, except for a significantly lower rate of myelotoxic effects in the group taking acetylcysteine (P=0.03). Therapy with acetylcysteine at a dose of 600 mg three times daily, added to prednisone and azathioprine, preserves vital capacity and DLCO in patients with idiopathic pulmonary fibrosis better than does standard therapy alone.Keywords
This publication has 47 references indexed in Scilit:
- Mechanisms of Pulmonary FibrosisAnnual Review of Medicine, 2004
- Idiopathic Pulmonary FibrosisDrugs, 2004
- Future Research Directions in Idiopathic Pulmonary FibrosisAmerican Journal of Respiratory and Critical Care Medicine, 2002
- Histopathologic Variability in Usual and Nonspecific Interstitial PneumoniasAmerican Journal of Respiratory and Critical Care Medicine, 2001
- Idiopathic Pulmonary FibrosisThe New England Journal of Medicine, 2001
- Idiopathic Pulmonary Fibrosis: Prevailing and Evolving Hypotheses about Its Pathogenesis and Implications for TherapyAnnals of Internal Medicine, 2001
- Colchicine versus Prednisone in the Treatment of Idiopathic Pulmonary FibrosisAmerican Journal of Respiratory and Critical Care Medicine, 1998
- Prognostic Significance of Histopathologic Subsets in Idiopathic Pulmonary FibrosisAmerican Journal of Respiratory and Critical Care Medicine, 1998
- Determinants of survival in idiopathic pulmonary fibrosis.American Journal of Respiratory and Critical Care Medicine, 1994
- Azathioprine Combined with Prednisone in the Treatment of Idiopathic Pulmonary Fibrosis: A Prospective Double-blind, Randomized, Placebo-controlled Clinical TrialAmerican Review of Respiratory Disease, 1991